Latest California Healthline Stories
California Wants to Slash Insulin Prices by Becoming a Drugmaker. Can it Succeed?
Gov. Gavin Newsom proposed spending $100 million to make insulin affordable to millions of people with diabetes under a new state generic drug label, CalRx. But state officials haven’t said how much the insulin will cost patients or how the state will deal with distribution and other challenges.
California quiere producir su propia insulina para bajar su alto costo, ¿lo conseguirá?
La administración del gobernador Gavin Newsom señaló que aproximadamente 4 millones de californianos han sido diagnosticados con diabetes, una enfermedad que puede destruir órganos, la vista y llevar a amputaciones si no se controla. La meta es prevenirlo con insulina más económica.
KHN’s ‘What the Health?’: Washington’s Slow Churn
Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts, or wherever you listen to podcasts. Click here for a transcript of the episode. In the wake of three high-profile mass shootings in less than a month, lawmakers on Capitol Hill have renewed […]
Medicare Drug Plan Prices Touted During Open Enrollment Can Rise Within a Month
Even the savviest Medicare drug plan shoppers can get a shock when they fill prescriptions: That great deal on medications is no bargain after prices go up.
Journalists Cover the Gamut, From Rising Insulin Costs to Delays in Autism Care for Kids
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
US Rep. Gaetz’s Diagnosis of What’s Driving Insulin Costs Misses the Root Cause
A diabetes diagnosis is not always related to a person’s weight or overall health, especially for those with Type 1 diabetes, who are dependent on insulin treatment for life.
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
KHN’s ‘What the Health?’: News You Might Have Missed
Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicare’s coverage decision for the controversial Alzheimer’s disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
KHN’s ‘What the Health?’: Finally, a Fix for the ‘Family Glitch’
President Joe Biden welcomed former President Barack Obama back to the White House this week to announce a new policy for the Affordable Care Act that would make subsidies available to more families with unaffordable employer coverage. Meanwhile, Congress struggled to find a compromise for continued federal funding of covid-19 vaccines, testing, and treatments. Tami Luhby of CNN, Shefali Luthra of The 19th, and Jessie Hellmann of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
Big Pharma Is Betting on Bigger Political Ambitions From Sen. Tim Scott
The South Carolina senator led the congressional pack in pharma campaign contributions for the second half of 2021. There are clear reasons.